Compare GRWG & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRWG | VTVT |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 104.9M |
| IPO Year | 2015 | 2015 |
| Metric | GRWG | VTVT |
|---|---|---|
| Price | $1.27 | $21.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.50 | ★ $56.00 |
| AVG Volume (30 Days) | ★ 283.3K | 14.2K |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $193,365,479.00 | N/A |
| Revenue This Year | $2.33 | N/A |
| Revenue Next Year | $3.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.51 | N/A |
| 52 Week Low | $1.01 | $20.56 |
| 52 Week High | $2.40 | $44.00 |
| Indicator | GRWG | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 31.19 | 22.64 |
| Support Level | $1.04 | N/A |
| Resistance Level | $1.58 | $34.65 |
| Average True Range (ATR) | 0.08 | 1.40 |
| MACD | -0.01 | -0.34 |
| Stochastic Oscillator | 30.43 | 4.59 |
GrowGeneration Corp owns and operates specialty retail stores focused on hydroponic and organic gardening. The company markets and distributes nutrients, growing media, indoor and greenhouse lighting, ventilation systems, and related accessories. It operates through two reportable segments: Cultivation and Gardening, which includes its hydroponic and organic gardening business, and Storage Solutions, which includes its benching, racking, and storage solutions operations. The company generates revenue mainly from the sale of proprietary and non-proprietary products through retail stores, e-commerce platforms, wholesale distribution, and commercial sales, along with the sale and installation of commercial fixtures.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.